CTI BioPharma Corp (CTIC) Stock: What Does the Chart Say Friday?

Friday, June 02, 2023 01:26 PM | InvestorsObserver Analysts

Mentioned in this article

CTI BioPharma Corp (CTIC) Stock: What Does the Chart Say Friday?

Overall market sentiment has been high on CTI BioPharma Corp (CTIC) stock lately. CTIC receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.

CTI BioPharma Corp has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on CTIC!

See Full CTIC Report

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With CTIC Stock Today?

CTI BioPharma Corp (CTIC) stock is down -0.06% while the S&P 500 has gained 1.42% as of 1:25 PM on Friday, Jun 2. CTIC is lower by -$0.01 from the previous closing price of $9.05 on volume of 853,180 shares. Over the past year the S&P 500 has gained 4.38% while CTIC has gained 52.36%. CTIC lost -$0.58 per share in the over the last 12 months.

More About CTI BioPharma Corp

CTI BioPharma Corp is a biopharmaceutical company focused on the acquisition, development, and commercialization of less toxic and more effective cancer therapies. Its therapeutic area is blood-related cancers. Its products under pipeline include PIXUVRI, and Pacritinib. PIXUVRI is a novel aza-anthracenedione with unique structural and physiochemical properties. Pacritinib is an investigational oral kinase inhibitor for the treatment of adult patients with myelofibrosis. Click Here to get the full Stock Report for CTI BioPharma Corp stock.